Catheter Precision, Inc. engages in the design, manufacture and sale of medical devices and technologies for cardiac electrophysiology. The company is headquartered in Fort Mill, South Carolina and currently employs 22 full-time employees. The company went IPO on 2018-09-27. The firm is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The firm's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. The company is developing technology for the treatment of acute decompensated heart failure.
Follow-Up Questions
What is the price performance of VTAK stock?
The current price of VTAK is $0, it has decreased 0% in the last trading day.
What is Catheter Precision Inc market cap?
Catheter Precision Inc's current market cap is $NaN
Is Catheter Precision Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Catheter Precision Inc, including 3 strong buy, 3 buy, 1 hold, 0 sell, and 3 strong sell
